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a round hole?Joel D. Cooper, MDIn 1995, Time magazine published an article entitled ‘‘Are
Surgeons Too Creative?’’ that examined the question of
whether new operations should be regulated. The public
and other interested parties are somewhat sympathetic to
this article’s premise, namely, that new surgical procedures
should require a similar level of evidence as is required for
introduction of new drugs.
In the 1990s, there was a new impetus in the movement
for ‘‘evidence-based medicine.’’ This phrase appeared for
the first time on a keyword search of PubMed in 1992
when there were 2 citations using this phrase. By 2001
a similar search revealed 2000 such citations.1 Clinical trials
became the basis for evidence-based medicine, and the ran-
domized clinical trial (RCT) was regarded as the highest
standard of all. Evidence from clinical trials was increas-
ingly used to establish clinical guidelines, defined as system-
atically developed statements to help practitioners and
patients decide on appropriate healthcare for specific clinical
conditions or circumstances.
The first RCT, reported in 1948, was designed to study the
effects of streptomycin in patients with tuberculosis. Such
trials have primarily been applied to analyzing the risks
and benefits of a new medical treatment. The application
of RCTs to surgical procedures has been much more limited.
However, RCTs are subject to many limitations and defi-
ciencies in general, and for surgical procedures in particular.
There are obvious differences between drugs and opera-
tions. A new drug does not change over time, is associated
with a variable biologic response, and often requires large
numbers of patients and considerable follow-up for assess-
ment. A new drug may manifest unforeseen late side effects
and toxicities far removed from the time of initial use. In
contrast, none of these characteristics apply to most surgical
procedures. A surgical intervention changes over time as
technique and experience evolve and as refinements are
made in patient selection and preoperative and postoperative
management. With this evolution comes a change in risk
over time. RCTs require a relatively long time frame and may
not yield results for years. This may restrict the evolution of
a new procedure or incorporation of new technology during
the course of the trial.From the Hospital of the University of Pennsylvania, Philadelphia, Pa.
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The Journal of Thoracic and CaRCTs in surgery, especially multicenter trials, are ex-
tremely expensive. Small trials cost hundreds of thousands
of dollars, and larger ones may cost millions of dollars.
The results are often not generalizable because strict inclu-
sion and exclusion criteria, and a steep learning curve for
some procedures, may make results of the trial not applica-
ble to a wider range of patients or surgeons. The ease of
blinding or double-blinding an RCT, routine for evaluating
medical treatments, rarely can be duplicated for most surgi-
cal procedures. Thus, the provision of a placebo for the con-
trol group, which requires a sham operation for surgical
trials, is a major problem. In the absence of a sham surgical
procedure, the large placebo effect often associated with the
surgical procedures may be misconstrued as confirming the
value of the procedure. This is particularly true when the out-
come measure relates to subjective improvement without
predefined, objective measurable end points.
A major limitation of RCTs in surgery is the difficulty, if
not impossibility, of standardizing the procedure being eval-
uated. There is surgeon to surgeon variation in terms of both
surgical approach and technical ability and experience. The
preoperative and postoperative care may vary from center to
center. Poor-quality surgery or care represents failure to de-
liver the intended treatment, and the trial may then measure
the deliverability and not the efficacy of the treatment. Evo-
lution in technical modification, risk, and selection criteria is
likely to occur in a course of a prolonged clinical trial. Sur-
gical procedures typically progress via such modifications
that individually are unlikely to produce detectable benefits
but that collectively may do so.
One of the most difficult issues to address is the timing of
an RCT for new surgical procedures. If the trial is done too
soon during the evolution of the procedure, or before the
trial surgeons have mastered the technique, emerging proce-
dures that have ultimately proved successful may have been
discarded because of poor or questionable early results.2 If
done too late, the new procedure may have gained wide-
spread acceptance, to the point where an RCT between a sur-
gical and medical therapy, or between 2 surgical procedures,
may be impossible to conduct. On the surgeon’s side, there
may be selection bias so that patients are diverted from en-
tering the trial because one arm is perceived to be better
than the other. On the patient’s side there may be refusal
to accept the assigned arm if results from nonrandomized
trials to date have seemingly confirmed the benefits of the
one arm of the trial.
Other weaknesses of the RCTs include ethical limitations
on the types of comparison that can be undertaken; therdiovascular Surgery c Volume 140, Number 4 743
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trial protocols; the problems of applicability to the general
population; type 2 errors and other statistical design faults;
publication bias; misuse and limitations of statistics; fraud;
maintenance of blinding; asking the wrong question; and
a simplistic, reductionist view of clinical management. The
concentration on the randomized controlled trial devalues
information from other sources, such as natural history stud-
ies, clinical experience, and case reports.3
Although the inability to apply RCTs to many surgical
procedures may be regrettable, the misinformation derived
from a flawed RCT may promote and perpetuate an inappro-
priate procedure for some time. Inappropriate conclusions
may be due to flaws in design, inherent limitations in the
trial, erroneous interpretation of results, or even chance oc-
currence, which dictates that 1 of the 20 ‘‘significant’’ study
findings with a P value less than .05 between the 2 arms may
be nothing more than random occurrence.
An oft-cited example of a flawed RCT is the Mayo lung
cancer screening trial, which failed to demonstrate survival
benefit from lung cancer in a randomized trial that assigned
half of the patients to regularly scheduled chest x-rays and
the other half to serve as controls. The study was underpow-
ered because it could detect only a 50% reduction in mortal-
ity. Some 25% of patients assigned to the radiologic
screening group did not comply, and 50% of the control
group happened to have an annual chest x-ray unrelated to
the trial. However, the results of this trial have helped perpet-
uate the notion that radiologic screening for detection of
early lung cancer has no value for the cancer that causes
more deaths in the United States than the next 3 most com-
mon cancers combined.
The opposite result, namely, the approval and application
of a highly controversial procedure, transmyocardial laser
revascularization for intractable angina in patients with
unreconstructable coronary circulation, was based on the
results of RCTs.4,5
The procedure, done under general anesthesia with an
open chest, involves multiple applications of a laser beam
to create small channels in the myocardium. The control
group was treated with medical management. The surgical
group demonstrated significant reduction in angina but no
demonstrable benefit in terms of measurable cardiac func-
tion, survival, or other relevant objective data that might
be correlated with symptomatic improvement. It is illustra-
tive to review the 2 reported randomized trials from the
1950s, comparing ligation of the internal thoracic artery
with a sham surgical procedure in which the artery was ex-
posed but not ligated. These trials were prompted by the rec-
ognition that medical trials for angina pectoris showed that
many patients responded remarkably to placebo medication.
After the introduction of internal thoracic ligation in Italy,
the procedure was enthusiastically accepted by some Amer-
ican surgeons and even hailed in a Reader’s Digest article.6744 The Journal of Thoracic and Cardiovascular SurgA proposed physiologic explanation for the benefit was that
blood from the thoracic arteries proximal to the site of liga-
tion would be diverted to the coronary circulation through
collateral channels. In 1958 Dimond and coworkers7 pre-
sented an abstract reporting on 18 patients with exertional
angina, with 13 undergoing the ligation procedure and 5 un-
dergoing a sham surgical procedure in a blinded fashion.
Marked improvement occurred in 10 of the ligated patients
and all 5 of the sham patients. A significant increase in exer-
cise tolerance occurred in 10 of the ligated patients and 5 of
the sham patients. Overall, the use of nitroglycerin was di-
minished in both groups.
Presentation of this abstract was followed by a publication
in The New England Journal of Medicine by Cobb and
coworkers,8 in which 17 patients with severe effort-induced
angina were randomized to internal thoracic artery ligation
or a sham operation. Neither the patient nor the physician eval-
uating the patient’s postoperative experience was aware of
which procedure had been performed. Results showed that
the number of nitroglycerin tablets used was reduced by
42% in those whose arteries were not ligated and by 34%
in those whose arteries were ligated. Five patients in each
group reported significant improvement after surgery. This
landmark study is considered the first randomized surgical trial
to show the powerful placebo effect of surgical procedures.
Randomized trials are poorly suited for evaluating surgi-
cal procedures, and this is one of the reasons why less than
7% of published surgical trials are randomized control trials,
and of these, the quality of the trial is very low.1,9-11 Pride,
independence, economic incentive, recognition, and
academic advancement may play a role in diverting
surgeons from RCTs to individual reports of case series.
‘‘Cynics might even claim that the personal attributes that
go to make a successful surgeon differ from those needed
for collaborative multi-center research.’’12
ALTERNATIVES TO RANDOMIZED CLINICAL
TRIALS
Undoubtedly, the evidence that has led to a change in
practice or adoption of a new procedure has come primarily
from observational data and reports of case series. This is
particularly true if the natural history of a disease or condi-
tion is well established and a series of cases are operated
on and produce a better clinical course. The effects of
some surgical procedures may be large and unlikely to be
the result of bias or other confounding factors. There is am-
ple evidence that nonrandomized trials can produce results
that correlate quite well with those of RCTs. Results from
well-designed observational studies have been shown to cor-
relate well with those from more expensive and impractical
RCTs for a wide variety of interventions.8,13,14
An example of a landmark case series was the demonstra-
tion of the value of the internal thoracic artery graft for
coronary bypass procedures. This publication by Loop andery c October 2010
Cooper Controversies in Cardiothoracic Surgeryco-authors,15 including 10-year survival data, has had a ma-
jor impact on current practice.
The value of a case series is particularly appropriate when
all alternative therapy has been exhausted, the natural his-
tory of the condition is well documented and the impact of
the surgical intervention is obvious, and the magnitude of
the effect is measurable, significant, and expected.
RANDOMIZED TRIALS VERSUS CASE SERIES
Although RCTs may have a limited role to play in sur-
gery, there are circumstances in which they may be abso-
lutely essential to provide the evidence needed for the role
and value of a surgical procedure.
When an operation is done to reduce the potential for a fu-
ture adverse event, a randomized trial is required. An excel-
lent example is the trial of endarterectomy for asymptomatic
carotid artery stenosis. For patients with a 60% or greater ca-
rotid stenosis, patients were randomized to either carotid
endarterectomy or aspirin and medical management. The
5-year stroke rate was 5.1% for endarterectomy and 11%
for the control arm, thus confirming the value of the surgical
procedure.
On the opposite side, arthroscopic surgery for the relief of
symptoms due to chronic arthritis of the knee was demon-
strated to be no better than a sham operation. This study il-
lustrates the importance of a blinded, sham-controlled
surgical procedure when the outcome to be measured is
primarily subjective, that is, relief of symptoms.
When a new surgical procedure is proposed as an alterna-
tive to an existing procedure, and both are designed to
produce the same result, an RCT should be encouraged.
The blinded RCT of laparoscopic versus open cholecystec-
tomy reported by Majeed and colleagues16 in 1996 demon-
strated no reduced pain, hospital stay, or narcotic use in the
laparoscopic group compared with the open group. Despite
this, the tidal wave of minimally invasive surgical proce-
dures, often based on the unproven presumption that small
incisions are invariably and de facto better than a larger in-
cision, is testimony to the many and complex factors that
drive the new technology. Perhaps this is one of the best ar-
guments for the need of more evidence-based guidance for
surgical procedures where surgeons’ eagerness to provide
a new operation may seem more related to commercial
concerns than to concerns for patients.
For oncology trials, where the anticipated benefit relates
to long-term results, such as survival or time to recurrence,
RCTs may be essential especially when comparisons of
surgery alone versus surgery plus adjuvant chemotherapy
or radiotherapy are to be made. The small but proven incre-
mental improvement in outcomes over a period of time
have formed the basis for significant progress in the field
of surgical oncology. Indeed, surgeons more readily recruit
patients for oncology trials than they do for trials of surgi-
cal technique.The Journal of Thoracic and CaCase series should be used whenever possible when a new
surgical procedure is introduced for a condition having no
alternative surgical option. Case series are also appropriate
when the natural history of the underlying condition is
well documented, the impact of the intervention is obvious,
and objective data can be used to compare patients’ preoper-
ative and postoperative status. Case series are also ideal after
animal studies demonstrating that the proposed procedure is
feasible, has a physiologic rational, and has demonstrable
efficacy.
CONCLUSIONS
Surgery remains an art as well as a science. Evidence-
based practice is the judicious use of available evidence to
assist in decision making about the care of individual pa-
tients. It is not prescriptive or ‘‘cookbook’’ medicine and
can never replace the surgeon’s experience and judgment
as to the value of the evidence and its relevance to the care
of any individual patient. RCTs are only one such form of
evidence, along with case reports, well-designed clinical
studies, expert panel consensus, and other types of scientific
evidence. The RCT has an important but limited role to play,
but is not the tool we need to support guidelines for surgical
practice. To invest the RCT with dogma that it is the only
valid method for confirming the value of new procedures
is to disguise it with the emperor’s new clothes. This, how-
ever, does not free us up to abandon the need to obtain sci-
entific evidence to support our decisions whenever possible.
Rather, we must seek to find alternative, practical, and
acceptable alternatives if we are to retain our academic cred-
ibility. We must work with epidemiologists and statisticians
to design appropriate trials, recognize that many clinical tri-
als are badly flawed, resist the tyranny of the RCT, and rec-
ognize that at best the conclusions are only guidelines and
at worst the result of a flawed trial rather than of a flawed
intervention.
How then should new surgical procedures be introduced
into general practice?
It used to be that new surgical procedures, often touted as
the latest ‘‘cure,’’ soon proved of little value and were dis-
carded by a process of natural selection. One of my mentors,
Ronald Belsey, used to note that ‘‘the follow-up clinics are
the shoals upon which founder many attractive theories in
surgery.’’ Thus, procedures designed to improve subjective
symptoms in patients with chronic obstructive pulmonary
disorder, such as glomectomy, radical hilar stripping, costo-
chondrectomy, phrenicectomy, pleural abrasion, and others,
were soon discarded into the wastebasket of history when
objective evidence was lacking and clinical experience
failed to confirm their value. I am concerned that today the
life span of unproven technologies and procedures may be
artificially prolonged by factors, including results from
flawed trials, competition for patients, economic conse-
quences, marketing and publicity often driven by industryrdiovascular Surgery c Volume 140, Number 4 745
Controversies in Cardiothoracic Surgery Coopersponsors, and confusing and often misleading information
on the Internet.
Now more than ever, I believe that we require methods to
study and validate the role of new and existing surgical inter-
ventions. An RCT is by and large not a suitable instrument
with which to achieve this goal. As noted by Lantos,17
from The University of Chicago, ‘‘.our statisticians en-
courage clinical investigators to design trials that make their
(statisticians) lives a little too easy by making our lives more
difficult. Rather than constraining human choices to meet the
needs of statisticians, I think we should encourage the statis-
ticians to devise methods of evaluating the source of choices
that free and intelligent citizens make all the time.’’
I propose the following for the introduction of new surgi-
cal procedures:
1. Health care providers should restrict the application
of promising new procedures to a limited number of
centers of excellence with appropriate resources and
experience.
2. Centers should be required to document and report at
regular intervals specified information regarding mor-
bidity, mortality, and objective measures of income.
3. These data should be periodically reviewed and eval-
uated by an independent scientific panel.
By these means, new procedures can be offered to appro-
priate patients, insurers and patients can be protected against
abuse, and the necessary data can be acquired for objective
analysis before widespread promulgation of the procedure
can occur. Then too, we as surgeons can take increased pride
in the remarkable accomplishments that our profession has
achieved.746 The Journal of Thoracic and Cardiovascular SurgReferences
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